The role of dietary histone deacetylases (HDACs) inhibitors in health and disease

Nutrients

Volumn 6, Issue 10, 2014, Pages 4273-4301

  Bassett, Shalome A ^a,b   Barnett, Matthew P G ^a,b  

^a AGRESEARCH GRASSLANDS   (New Zealand)

^b Nutrigenomics New Zealand   (New Zealand)

Author keywords

Histone deacetylase; Histone deacetylase inhibitors; Lysine deacetylase; Nutritional epigenetics

Indexed keywords

ALLICIN; ARGININE; DEUBIQUITINASE; GLUTAMIC ACID; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; PROLINE; REACTIVE OXYGEN METABOLITE; SERINE; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; THREONINE; TRICHOSTATIN A; UNINDEXED DRUG; HISTONE; TRANSCRIPTION FACTOR;

ACETYLATION; ADENOSINE DIPHOSPHATE RIBOSYLATION; CAENORHABDITIS ELEGANS; CHROMATIN; DEACETYLATION; DEAMINATION; DIETARY INTAKE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DNA TRANSCRIPTION; ENZYME POLYMORPHISM; EPIGENETICS; GENE EXPRESSION; GENETIC VARIABILITY; HISTONE MODIFICATION; HODGKIN DISEASE; HUMAN; HUNTINGTON CHOREA; ISOMERIZATION; MASS SPECTROMETRY; METHYLATION; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUMOYLATION; UBIQUITINATION; DIET THERAPY; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; MENTAL DISEASE; METABOLISM; NEUROLOGIC DISEASE;

ACETYLATION; DIET THERAPY; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; TRANSCRIPTION FACTORS;

EID: 84908217408     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6104273     Document Type: Review

References (162)

1. Blewitt, M.; Whitelaw, E. The use of mouse models to study epigenetics. Cold Spring Harb. Perspect. Biol. 2013, 5, a017939.
2. Coppede, F. The role of epigenetics in colorectal cancer. Expert Rev. Gastroenterol. Hepatol. 2014, doi:10.1586/17474124.2014.924397.
3. Simoes-Pires, C.; Zwick, V.; Nurisso, A.; Schenker, E.; Carrupt, P.-A.; Cuendet, M. HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs? Mol. Neurodegener. 2013, 8, 7.
4. Glauben, R.; Batra, A.; Stroh, T.; Erben, U.; Fedke, I.; Lehr, H.A.; Leoni, F.; Mascagni, P.; Dinarello, C.A.; Zeitz, M.; et al. Histone deacetylases: Novel targets for prevention of colitis-associated cancer in mice. Gut 2008, 57, 613-622.
5. Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res. 2007, 5, 981-989.
6. Kim, H.J.; Bae, S.C. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3, 166-179.
7. Levene, P.A. On the chemistry of the chromatin substance of the nerve cell. J. Med. Res. 1903, 10, 204-211.
8. Moore, B.; Whitley, E.; Webster, A. The basic and acidic proteins of the sperm of Echinus esculentus. Direct measurements of the osmotic pressure of a protamine or histone. Biochem. J. 1913, 7, 142-147.
9. Mirsky, A.E.; Pollister, A.W. Chromosin, a desoxyribose nucleoprotein complex of the cell nucleus. J. Gen. Physiol. 1946, 30, 117-148.
10. Mellor, J. Dynamic nucleosomes and gene transcription. Trends Genet. 2006, 22, 320-329.
11. Gershey, E.L.; Vidali, G.; Allfrey, V.G. Chemical studies of histone acetylation. The occurrence of epsilon-N-acetyllysine in the f2a1 histone. J. Biol. Chem. 1968, 243, 5018-5022.
12. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693-705.
13. Andreu-Vieyra, C.V.; Liang, G. Nucleosome occupancy and gene regulation during tumorigenesis. Adv. Exp. Med. Biol. 2013, 754, 109-134.
14. Barnett, M.P.G.; Bassett, S.A.; Bermingham, E.N. Epigenetics-What role could this play in functional foods and personalized nutrition? In Nutrigenomics and Nutrigenetics in Functional Foods and Personalized Nutrition; Ferguson, L.R. Ed.; CRC Press: Florence, KY, USA, 2013; pp. 243-267.
15. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32-42.
16. Ho, E.; Dashwood, R.H. Dietary manipulation of histone structure and function. World Rev. Nutr. Diet. 2010, 101, 95-102.
17. Xu, F.; Zhang, K.; Grunstein, M. Acetylation in histone H3 globular domain regulates gene expression in yeast. Cell 2005, 121, 375-385.
18. Glozak, M.A.; Seto, E. Histone deacetylases and cancer. Oncogene 2007, 26, 5420-5432.
19. Xu, W.S.; Parmigiani, R.B.; Marks, P.A. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007, 26, 5541-5552.
20. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E.C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA 2004, 101, 15064-15069.
21. Yamamoto, H.; Schoonjans, K.; Auwerx, J. Sirtuin functions in health and disease. Mol. Endocrinol. 2007, 21, 1745-1755.
22. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73, 417-435.
23. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191-196.
24. Porcu, M.; Chiarugi, A. The emerging therapeutic potential of sirtuin-interacting drugs: From cell death to lifespan extension. Trends Pharmacol. Sci. 2005, 26, 94-103.
25. Shoba, B.; Lwin, Z.M.; Ling, L.S.; Bay, B.H.; Yip, G.W.; Kumar, S.D. Function of sirtuins in biological tissues. Anat. Rec. 2009, 292, 536-543.
26. Huang, J.Y.; Hirschey, M.D.; Shimazu, T.; Ho, L.; Verdin, E. Mitochondrial sirtuins. Biochim. Biophys. Acta 2010, 8, 7.
27. Verdin, E.; Hirschey, M.D.; Finley, L.W.; Haigis, M.C. Sirtuin regulation of mitochondria: Energy production, apoptosis, and signaling. Trends Biochem. Sci. 2010, 35, 669-675.
28. Adimoolam, S.; Sirisawad, M.; Chen, J.; Thiemann, P.; Ford, J.M.; Buggy, J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. USA 2007, 104, 19482-19487.
29. Claus, R.; Lubbert, M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003, 22, 6489-6496.
30. Khan, O.; La Thangue, N.B. Drug Insight: Histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Prac. Oncol. 2008, 5, 714-726.
31. Bannister, A.J.; Kouzarides, T. Reversing histone methylation. Nature 2005, 436, 1103-1106.
32. Nottke, A.; Colaiácovo, M.P.; Shi, Y. Developmental roles of the histone lysine demethylases. Dev. Change 2009, 136, 879-889.
33. Chang, B.; Chen, Y.; Zhao, Y.; Bruick, R.K. JMJD6 is a histone arginine demethylase. Science 2007, 318, 444-447.
34. Cao, R.; Tsukada, Y.I.; Zhang, Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol. Cell 2005, 20, 845-854.
35. Wang, H.; Zhai, L.; Xu, J.; Joo, H.Y.; Jackson, S.; Erdjument-Bromage, H.; Tempst, P.; Xiong, Y.; Zhang, Y. Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol. Cell 2006, 22, 383-394.
36. Cao, J.; Yan, Q. Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front. Oncol. 2012, 2, 26.
37. Liu, H.W.; Zhang, J.; Heine, G.F.; Arora, M.; Gulcin Ozer, H.; Onti-Srinivasan, R.; Huang, K.; Parvin, J.D. Chromatin modification by SUMO-1 stimulates the promoters of translation machinery genes. Nucleic Acids Res. 2012, 40, 10172-10186.
38. Drag, M.; Salvesen, G.S. DeSUMOylating enzymes-SENPs. IUBMB Life 2008, 60, 734-742.
39. Fillingham, J.; Keogh, M.C.; Krogan, N.J. GammaH2AX and its role in DNA double-strand break repair. Biochem. Cell Biol. 2006, 84, 568-577.
40. Rossetto, D.; Avvakumov, N.; Côté, J. Histone phosphorylation: A chromatin modification involved in diverse nuclear events. Epigenetics 2012, 7, 1098-1108.
41. Nakada, S.; Chen, G.I.; Gingras, A.C.; Durocher, D. PP4 is a γH2AX phosphatase required for recovery from the DNA damage checkpoint. EMBO Rep. 2008, 9, 1019-1026.
42. Denis, H.; Deplus, R.; Putmans, P.; Yamada, M.; Métivier, R.; Fuks, F. Functional connection between deimination and deacetylation of histones. Mol. Cell. Biol. 2009, 29, 4982-4993.
43. Cuthbert, G.L.; Daujat, S.; Snowden, A.W.; Erdjument-Bromage, H.; Hagiwara, T.; Yamada, M.; Schneider, R.; Gregory, P.D.; Tempst, P.; Bannister, A.J.; Kouzarides, T. Histone deimination antagonizes arginine methylation. Cell 2004, 118, 545-553.
44. Wang, Y.; Wysocka, J.; Sayegh, J.; Lee, Y.H.; Perlin, J.R.; Leonelli, L.; Sonbuchner, L.S.; McDonald, C.H.; Cook, R.G.; Dou, Y.; Roeder, R.G.; Clarke, S.; Stallcup, M.R.; Allis, C.D.; Coonrod, S.A. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004, 306, 279-283.
45. Hassa, P.O.; Haenni, S.S.; Elser, M.; Hottiger, M.O. Nuclear ADP-ribosylation reactions in mammalian cells: Where are we today and where are we going? Microbiol. Mol. Biol. Rev. 2006, 70, 789-829.
46. Kassner, I.; Barandun, M.; Fey, M.; Rosenthal, F.; Hottiger, M.O. Crosstalk between SET7/9-dependent methylation and ARTD1-mediated ADP-ribosylation of histone H1.4. Epigenetics Chromatin 2013, 6, 1.
47. Nelson, C.J.; Santos-Rosa, H.; Kouzarides, T. Proline isomerization of histone H3 regulates lysine methylation and gene expression. Cell 2006, 126, 905-916.
48. Raghuram, N.; Strickfaden, H.; McDonald, D.; Williams, K.; Fang, H.; Mizzen, C.; Hayes, J.J.; Th'ng, J.; Hendzel, M.J. Pin1 promotes histone H1 dephosphorylation and stabilizes its binding to chromatin. J. Cell Biol. 2013, 203, 57-71.
49. Newkirk, T.L.; Bowers, A.A.; Williams, R.M. Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors. Nat. Prod. Rep. 2009, 26, 1293-1320.
50. Gui, C.-Y.; Ngo, L.; Xu, W.S.; Richon, V.M.; Marks, P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 2004, 101, 1241-1246.
51. Jin, K.L.; Pak, J.H.; Park, J.-Y.; Choi, W.H.; Lee, J.-Y.; Kim, J.-H.; Nam, J.-H. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J. Gynecol. Oncol. 2008, 19, 185-190.
52. Adams, H.; Fritzsche, F.R.; Dirnhofer, S.; Kristiansen, G.; Tzankov, A. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin. Ther. Targets 2010, 14, 577-584.
53. Song, Y.; Shiota, M.; Tamiya, S.; Kuroiwa, K.; Naito, S.; Tsuneyoshi, M. The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology 2011, 58, 773-780.
54. Sudo, T.; Mimori, K.; Nishida, N.; Kogo, R.; Iwaya, T.; Tanaka, F.; Shibata, K.; Fujita, H.; Shirouzu, K.; Mori, M. Histone deacetylase 1 expression in gastric cancer. Oncol. Rep. 2011, 26, 777-782.
55. Ozdag, H.; Teschendorff, A.; Ahmed, A.; Hyland, S.; Blenkiron, C.; Bobrow, L.; Veerakumarasivam, A.; Burtt, G.; Subkhankulova, T.; Arends, M.; et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006, 7, 90.
56. Ropero, S.; Fraga, M.F.; Ballestar, E.; Hamelin, R.; Yamamoto, H.; Boix-Chornet, M.; Caballero, R.; Alaminos, M.; Setien, F.; Paz, M.F.; et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006, 38, 566-569.
57. Barnes, P.J.; Adcock, I.M.; Ito, K. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur. Respir. J. 2005, 25, 552-563.
58. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S.C.; Carey, N.; et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409, 581-589.
59. Noh, H.; Oh, E.Y.; Seo, J.Y.; Yu, M.R.; Kim, Y.O.; Ha, H.; Lee, H.B. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-β1-induced renal injury. Am. J. Physiol. Renal Physiol. 2009, 207, F729-F739.
60. Zeng, Z.; Liao, R.; Yao, Z.; Zhou, W.; Ye, P.; Zheng, X.; Li, X.; Huang, Y.; Chen, S.; Chen, Q. Three single nucleotide variants of the HDAC gene are associated with type 2 diabetes mellitus in a Chinese population: A community-based case-control study. Gene 2014, 533, 427-433.
61. Sun, Z.; Miller, R.A.; Patel, R.T.; Chen, J.; Dhir, R.; Wang, H.; Zhang, D.; Graham, M.J.; Unterman, T.G.; Shulman, G.I.; et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 2012, 18, 934-942.
62. Yang, X.-J.; Grégoire, S. Class II histone deacetylases: From sequence to function, regulation, and clinical implication. Mol. Cell. Biol. 2005, 25, 2873-2884.
63. Wang, W.-H.; Cheng, L.-C.; Pan, F.-Y.; Xue, B.; Wang, D.-Y.; Chen, Z.; Li, C.-J. Intracellular trafficking of histone deacetylase 4 regulates long-term memory formation. Anat. Rec. Hoboken 2011, 294, 1025-1034.
64. Kim, T.; Park, J.K.; Kim, H.-J.; Chung, J.-H.; Kim, J.W. Association of histone deacetylase genes with schizophrenia in Korean population. Psychiatry Res. 2010, 178, 266-269.
65. Deardorff, M.A.; Bando, M.; Nakato, R.; Watrin, E.; Itoh, T.; Minamino, M.; Saitoh, K.; Komata, M.; Katou, Y.; Clark, D.; et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. Nature 2012, 489, 313-317.
66. Sjöblom, T.; Jones, S.; Wood, L.D.; Parsons, D.W.; Lin, J.; Barber, T.D.; Mandelker, D.; Leary, R.J.; Ptak, J.; Silliman, N.; et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314, 268-274.
67. Leonart, M.; Vidal, F.; Gallardo, D.; Diaz-Fuertes, M.; Rojo, F.; Cuatrecasas, M.; López-Vicente, L.; Kondoh, H.; Blanco, C.; Carnero, A.; et al. New p53 related genes in human tumors: Significant downregulation in colon and lung carcinomas. Oncol. Rep. 2006, 16, 603-608.
68. Halkidou, K.; Gaughan, L.; Cook, S.; Leung, H.Y.; Neal, D.E.; Robson, C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59, 177-189.
69. Collins, S.A.; Lucas, J.S.A.; Inskip, H.M.; Godfrey, K.M.; Roberts, G.; Holloway, J.W.; The Southampton Women's Survey Study Group. HHIP, HDAC4, NCR3 and RARB polymorphisms affect fetal, childhood and adult lung function. Eur. Respir. J. 2013, 41, 756-757.
70. Villavicencio-Lorini, P.; Klopocki, E.; Trimborn, M.; Koll, R.; Mundlos, S.; Horn, D. Phenotypic variant of Brachydactyly-mental retardation syndrome in a family with an inherited interstitial 2q37.3 microdeletion including HDAC4. Eur. J. Hum. Genet. 2013, 21, 743-748.
71. Williams, S.R.; Aldred, M.A.; Der Kaloustian, V.M.; Halal, F.; Gowans, G.; McLeod, D.R.; Zondag, S.; Toriello, H.V.; Magenis, R.E.; Elsea, S.H. Haploinsufficiency of HDAC4 causes Brachydactyly mental retardation syndrome, with Brachydactyly type E, developmental delays, and behavioral problems. Am. J. Hum. Genet. 2010, 87, 219-228.
72. Mielcarek, M.; Landles, C.; Weiss, A.; Bradaia, A.; Seredenina, T.; Inuabasi, L.; Osborne, G.F.; Wadel, K.; Touller, C.; Butler, R.; et al. HDAC4 reduction: A novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 2013, 11, e1001717.
73. Cui, H.; Moore, J.; Ashimi, S.S.; Mason, B.L.; Drawbridge, J.N.; Han, S.; Hing, B.; Matthews, A.; McAdams, C.J.; Darbro, B.W.; Pieper, A.A.; Waller, D.A.; Xing, C.; Lutter, M. Eating disorder predisposition is associated with ESRRA and HDAC4 mutations. J. Clin. Investig. 2013, 123, 4706-4713.
74. Iga, J.-I.; Ueno, S.-I.; Yamauchi, K.; Numata, S.; Kinouchi, S.; Tayoshi-Shibuya, S.; Song, H.; Ohmori, T. Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 628-632.
75. Ouaissi, M.; Sielezneff, I.; Silvestre, R.; Sastre, B.; Bernard, J.P.; Lafontaine, J.S.; Payan, M.J.; Dahan, L.; Pirro, N.; Seitz, J.F.; Mas, E.; Lombardo, D.; Ouaissi, A. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann. Surg. Oncol. 2008, 15, 2318-2328.
76. Yan, K.; Cao, Q.; Reilly, C.M.; Young, N.L.; Garcia, B.A.; Mishra, N. Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. J. Biol. Chem. 2011, 286, 28833-28843.
77. David, D.; Cardoso, J.; Marques, B.Á.; Marques, R.; Silva, E.D.; Santos, H.; Boavida, M.G. Molecular characterization of a familial translocation implicates disruption of HDAC9 and possible position effect on TGFβ2 in the pathogenesis of Peters' anomaly. Genomics 2003, 81, 489-503.
78. Inkster, B.; Strijbis, E.M.M.; Vounou, M.; Kappos, L.; Radue, E.-W.; Matthews, P.M.; Uitdehaag, B.M.J.; Barkhof, F.; Polman, C.H.; Montana, G.; et al. Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. Neurobiol. Aging 2013, 34, 238-247.
79. Zhang, L.; Sheng, S.; Qin, C. The role of HDAC6 in Alzheimer's disease. J. Alzheimers Dis. 2013, 33, 283-295.
80. Gradilone, S.A.; Habringer, S.; Masyuk, T.V.; Howard, B.N.; Masyuk, A.I.; Larusso, N.F. HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am. J. Pathol. 2014, 184, 600-608.
81. Gloghini, A.; Buglio, D.; Khaskhely, N.M.; Georgakis, G.; Orlowski, R.Z.; Neelapu, S.S.; Carbone, A.; Younes, A. Expression of histone deacetylases in lymphoma: Implication for the development of selective inhibitors. Br. J. Haematol. 2009, 147, 515-525.
82. Wang, J.C.; Kafeel, M.I.; Avezbakiyev, B.; Chen, C.; Sun, Y.; Rathnasabapathy, C.; Kalavar, M.; He, Z.; Burton, J.; Lichter, S. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011, 81, 325-329.
83. Bosch-Presegue, L.; Vaquero, A. The dual role of sirtuins in cancer. Genes Cancer 2011, 2, 648-662.
84. Carafa, V.; Nebbioso, A.; Altucci, L. Sirtuins & disease: The road ahead. Front. Pharmacol. 2012, 3, 4.
85. Deng, C.X. SIRT1, is it a tumor promoter or tumor suppressor? Int. J. Biol. Sci. 2009, 5, 147-152.
86. Kuzmichev, A.; Margueron, R.; Vaquero, A.; Preissner, T.S.; Scher, M.; Kirmizis, A.; Ouyang, X.; Brockdorff, N.; Abate-Shen, C.; Farnham, P.; et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. USA 2005, 102, 1859-1864.
87. Lutz, M.I.; Milenkovic, I.; Regelsberger, G.; Kovacs, G.G. Distinct patterns of sirtuin expression during progression of Alzheimer's disease. Neuromolecular Med. 2014, 16, 405-414.
88. Du, J.; Zhou, Y.; Su, X.; Yu, J.J.; Khan, S.; Jiang, H.; Kim, J.; Woo, J.; Kim, J.H.; Choi, B.H.; et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 2011, 334, 806-809.
89. Peng, C.; Lu, Z.; Xie, Z.; Cheng, Z.; Chen, Y.; Tan, M.; Luo, H.; Zhang, Y.; He, W.; Yang, K.; et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol. Cell. Proteomics 2011, 10, doi:10.1074/mcp.M111.012658.
90. Osborne, B.; Cooney, G.J.; Turner, N. Are sirtuin deacylase enzymes important modulators of mitochondrial energy metabolism? Biochim. Biophys. Acta. 2014, 1840, 1295-1302.
91. Wei, W.; Xu, X.; Li, H.; Zhang, Y.; Han, D.; Wang, Y.; Yan, W.; Wang, X.; Zhang, J.; Liu, N.; You, Y. The SIRT2 Polymorphism rs10410544 and Risk of Alzheimer's Disease: A Meta-analysis. Neuromolecular Med. 2014, 16, 448-456.
92. Riccio, P. The molecular basis of nutritional intervention in multiple sclerosis: A narrative review. Complement. Ther. Med. 2011, 19, 228-237.
93. Riccio, P.; Rossano, R.; Liuzzi, G.M. May diet and dietary supplements improve the wellness of multiple sclerosis patients? A molecular approach. Autoimmune Dis. 2011, 24, 249842.
94. Yang, B.; Fu, X.; Shao, L.; Ding, Y.; Zeng, D. Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer. Biochem. Biophys. Res. Commun. 2014, 443, 156-160.
95. Vakhrusheva, O.; Braeuer, D.; Liu, Z.; Braun, T.; Bober, E. Sirt7-dependent inhibition of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J. Physiol. Pharmacol. 2008, 9, 201-212.
96. Ashraf, N.; Zino, S.; Macintyre, A.; Kingsmore, D.; Payne, A.P.; George, W.D.; Shiels, P.G. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer 2006, 95, 1056-1061.
97. Miremadi, A.; Oestergaard, M.Z.; Pharoah, P.D.; Caldas, C. Cancer genetics of epigenetic genes. Hum. Mol. Genet. 2007, 16 (R1), R28-R49.
98. Choi, J.H.; Kwon, H.J.; Yoon, B.I.; Kim, J.H.; Han, S.U.; Joo, H.J.; Kim, D.Y. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn. J. Cancer Res. 2001, 92, 1300-1304.
99. Wilson, A.J.; Byun, D.-S.; Popova, N.; Murray, L.B.; L'Italien, K.; Sowa, Y.; Arango, D.; Velcich, A.; Augenlicht, L.H.; Mariadason, J.M. Histone deacetylase 3 (HDAC3) and other Class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 2006, 281, 13548-13558.
100. Melchionda, L.; Fang, M.; Wang, H.; Fugnanesi, V.; Morbin, M.; Liu, X.; Li, W.; Ceccherini, I.; Farina, L.; Savoiardo, M.; et al. Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant. Orphanet J. Rare Dis. 2013, 8, 66.
101. Marquardt, J.U.; Fischer, K.; Baus, K.; Kashyap, A.; Ma, S.; Krupp, M.; Linke, M.; Teufel, A.; Zechner, U.; Strand, D.; Thorgeirsson, S.S.; Galle, P.R.; Strand, S. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 2013, 58, 1054-1064.
102. Riggs, M.G.; Whittaker, R.G.; Neumann, J.R.; Ingram, V.M. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977, 268, 462-464.
103. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
104. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
105. Yoshida, M.; Horinouchi, S.; Beppu, T. Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995, 17, 423-430.
106. Taunton, J.; Hassig, C.A.; Schreiber, S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272, 408-411.
107. Ververis, K.; Hiong, A.; Karagiannis, T.C.; Licciardi, P.V. Histone deacetylase inhibitors (HDACIs): Multitargeted anticancer agents. Biologics 2013, 7, 47-60.
108. Rajendran, P.; Ho, E.; Williams, D.E.; Dashwood, R.H. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin. Epigenetics 2011, 3, 4.
109. Licciardi, P.V.; Kwa, F.A.; Ververis, K.; Di Costanzo, N.; Balcerczyk, A.; Tang, M.L.; El-Osta, A.; Karagiannis, T.C. Influence of natural and synthetic histone deacetylase inhibitors on chromatin. Antioxid. Redox Signal. 2012, 17, 340-354.
110. Glauben, R.; Batra, A.; Fedke, I.; Zeitz, M.; Lehr, H.A.; Leoni, F.; Mascagni, P.; Fantuzzi, G.; Dinarello, C.A.; Siegmund, B. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 2006, 176, 5015-5022.
111. Banerjee, A.; Trivedi, C.M.; Damera, G.; Jiang, M.; Jester, W.; Hoshi, T.; Epstein, J.A.; Panettieri, R.A. Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am. J. Respir. Cell Mol. Biol. 2012, 46, 132-138.
112. Chuang, D.M.; Leng, Y.; Marinova, Z.; Kim, H.J.; Chiu, C.T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009, 32, 591-601.
113. Kong, Y.; Tannous, P.; Lu, G.; Berenji, K.; Rothermel, B.A.; Olson, E.N.; Hill, J.A. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113, 2579-2588.
114. Wetzel, M.; Premkumar, D.R.; Arnold, B.; Pollack, I.F. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. J. Neurosurg. 2005, 103, 549-556.
115. Krasteva, S.; Heiss, E.; Krenn, L. Optimization and application of a fluorimetric assay for the identification of histone deacetylase inhibitors from plant origin. Pharm. Biol. 2011, 49, 658-668.
116. Liu, Y.; Salvador, L.A.; Byeon, S.; Ying, Y.; Kwan, J.C.; Law, B.K.; Hong, J.; Luesch, H. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. J. Pharmacol. Exp. Ther. 2010, 335, 351-361.
117. Marks, P.A.; Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 2007, 25, 84-90.
118. Whittle, N.; Singewald, N. HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand? Biochem. Soc. Trans. 2014, 42, 569-581.
119. Anand, P.; Kunnumakara, A.; Sundaram, C.; Harikumar, K.; Tharakan, S.; Lai, O.; Sung, B.; Aggarwal, B. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 2008, 25, 2097-2116.
120. Gonzalez, C.A.; Riboli, E. Diet and cancer prevention: Contributions from the european prospective investigation into cancer and nutrition (EPIC) study. Eur. J. Cancer 2010, 46, 2555-2562.
121. Greenwald, P.; Clifford, C.K.; Milner, J.A. Diet and cancer prevention. Eur. J. Cancer 2001, 37, 948-965.
122. Yao, H.; Xu, W.; Shi, X.; Zhang, Z. Dietary flavonoids as cancer prevention agents. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2011, 29, 1-31.
123. Nilsson, A.C.; Ostman, E.M.; Knudsen, K.E.; Holst, J.J.; Bjorck, I.M. A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. J. Nutr. 2010, 140, 1932-1936.
124. Nian, H.; Bisson, W.H.; Dashwood, W.M.; Pinto, J.T.; Dashwood, R.H. Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis 2009, 30, 1416-1423.
125. Lee, J.I.; Nian, H.; Cooper, A.J.; Sinha, R.; Dai, J.; Bisson, W.H.; Dashwood, R.H.; Pinto, J.T. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev. Res. Phila. 2009, 2, 683-693.
126. Pinto, J.T.; Lee, J.I.; Sinha, R.; MacEwan, M.E.; Cooper, A.J. Chemopreventive mechanisms of alpha-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids 2011, 41, 29-41.
127. Cao, S.; Durrani, F.A.; Toth, K.; Rustum, Y.M. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models. Br. J. Cancer 2014, 110, 1733-1743.
128. Myzak, M.C.; Dashwood, R.H. Histone deacetylases as targets for dietary cancer preventive agents: Lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr. Drug Targets 2006, 7, 443-452.
129. Bhatnagar, N.; Li, X.; Chen, Y.; Zhou, X.; Garrett, S.H.; Guo, B. 3,3′-Diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev. Res. Phila. 2009, 2, 581-589.
130. Aggarwal, B.B.; Ichikawa, H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005, 4, 1201-1215.
131. Xiong, S.D.; Yu, K.; Liu, X.H.; Yin, L.H.; Kirschenbaum, A.; Yao, S.; Narla, G.; DiFeo, A.; Wu, J.B.; Yuan, Y.; Ho, S.-M.; Lam, Y.W.; Levine, A.C. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int. J. Cancer 2009, 125, 774-782.
132. Gopal, Y.N.V.; Arora, T.S.; Van Dyke, M.W. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem. Biol. 2007, 14, 813-823.
133. Lea, M.A.; Rasheed, M.; Randolph, V.M.; Khan, F.; Shareef, A.; desBordes, C. Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr. Cancer 2002, 43, 90-102.
134. Son, I.H.; Lee, S.I.; Yang, H.D.; Moon, H.-I. Bis(4-hydroxybenzyl)sulfide: A sulfur compound inhibitor of histone deacetylase isolated from root extract of Pleuropterus ciliinervis. Molecules 2007, 12, 815-820.
135. Waldecker, M.; Kautenburger, T.; Daumann, H.; Busch, C.; Schrenk, D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J. Nutr. Biochem 2008, 19, 587-593.
136. Thakur, V.S.; Gupta, K.; Gupta, S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis 2012, 33, 377-384.
137. Sbardella, G.; Castellano, S.; Vicidomini, C.; Rotili, D.; Nebbioso, A.; Miceli, M.; Altucci, L.; Mai, A. Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases. Bioorg. Med. Chem. Lett. 2008, 18, 2788-2792.
138. Lea, M.A.; Randolph, V.M.; Patel, M. Increased acetylation of histones induced by diallyl disulfide and structurally related molecules. Int. J. Oncol. 1999, 15, 347-352.
139. Druesne, N.; Pagniez, A.; Mayeur, C.; Thomas, M.; Cherbuy, C.; Duee, P.H.; Martel, P.; Chaumontet, C. Repetitive treatments of colon HT-29 cells with diallyl disulfide induce a prolonged hyperacetylation of histone H3 K14. Ann. N. Y. Acad. Sci. 2004, 1030, 612-621.
140. Hong, T.; Nakagawa, T.; Pan, W.; Kim, M.Y.; Kraus, W.L.; Ikehara, T.; Yasui, K.; Aihara, H.; Takebe, M.; Muramatsu, M.; et al. Isoflavones stimulate estrogen receptor-mediated core histone acetylation. Biochem. Biophys. Res. Commun. 2004, 317, 259-264.
141. Pandey, M.; Kaur, P.; Shukla, S.; Abbas, A.; Fu, P.; Gupta, S. Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study. Mol. Carcinog. 2012, 51, 952-962.
142. WAF1 by altering chromatin of STAT response element in A375 cells. BMC Cancer 2012, 12, 180.
143. Majid, S.; Dar, A.A.; Ahmad, A.E.; Hirata, H.; Kawakami, K.; Shahryari, V.; Saini, S.; Tanaka, Y.; Dahiya, A.V.; Khatri, G.; et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 2009, 30, 662-670.
144. Lea, M.A.; Randolph, V.M.; Lee, J.E.; desBordes, C. Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int. J. Cancer 2001, 92, 784-789.
145. Myzak, M.C.; Dashwood, W.M.; Orner, G.A.; Ho, E.; Dashwood, R.H. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 2006, 20, 506-508.
146. Son, I.H.; Chung, I.-M.; Lee, S.I.; Yang, H.D.; Moon, H.-I. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg. Med. Chem. Lett. 2007, 17, 4753-4755.
147. Priyadarsini, R.V.; Vinothini, G.; Murugan, R.S.; Manikandan, P.; Nagini, S. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr. Cancer 2011, 63, 218-226.
148. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430, 686-689.
149. Yang, S.R.; Wright, J.; Bauter, M.; Seweryniak, K.; Kode, A.; Rahman, I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: Implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292, L567-L576.
150. Chung, I.M.; Kim, M.Y.; Park, W.H.; Moon, H.I. Histone deacetylase inhibitors from the rhizomes of Zingiber zerumbet. Pharmazie 2008, 63, 774-776.
151. Chen, I.H.; Lu, M.C.; Du, Y.C.; Yen, M.H.; Wu, C.C.; Chen, Y.H.; Hung, C.S.; Chen, S.L.; Chang, F.R.; Wu, Y.C. Cytotoxic triterpenoids from the stems of Microtropis japonica. J. Nat. Prod. 2009, 72, 1231-1236.
152. Shukla, S.; Gupta, S. Apigenin: A promising molecule for cancer prevention. Pharm. Res. 2010, 27, 962-978.
153. Venturelli, S.; Berger, A.; Bocker, A.; Busch, C.; Weiland, T.; Noor, S.; Leischner, C.; Schleicher, S.; Mayer, M.; Weiss, T.S.; Bischoff, S.C.; Lauer, U.M.; Bitzer, M. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone proteins in human-derived hepatoblastoma cells. PLoS One 2013, 8, e73097.
154. Lee, S.J.; Krauthauser, C.; Maduskuie, V.; Fawcett, P.T.; Olson, J.M.; Rajasekaran, S.A. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 2011, 11, 144.
155. Morimoto, T.; Sunagawa, Y.; Kawamura, T.; Takaya, T.; Wada, H.; Nagasawa, A.; Komeda, M.; Fujita, M.; Shimatsu, A.; Kita, T.; Hasegawa, K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 2008, 118, 868-878.
156. Xiao, X.; Shi, D.; Liu, L.; Wang, J.; Xie, X.; Kang, T.; Deng, W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One 2011, 6, 8.
157. Rajendran, P.; Williams, D.E.; Ho, E.; Dashwood, R.H. Metabolism as a key to histone deacetylase inhibition. Crit. Rev. Biochem. Mol. Biol. 2011, 46, 181-199.
158. Myzak, M.C.; Tong, P.; Dashwood, W.M.; Dashwood, R.H.; Ho, E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp. Biol. Med. 2007, 232, 227-234.
159. Link, A.; Balaguer, F.; Goel, A. Cancer chemoprevention by dietary polyphenols: Promising role for epigenetics. Biochem. Pharmacol. 2010, 80, 1771-1792.
160. Cieślik, E.; Leszczyńska, T.; Filipiak-Florkiewicz, A.; Sikora, E.; Pisulewski, P.M. Effects of some technological processes on glucosinolate contents in cruciferous vegetables. Food Chem. 2007, 105, 976-981.
161. Lin, C.H.; Chang, C.Y. Textural change and antioxidant properties of broccoli under different cooking treatments. Food Chem. 2005, 90, 9-15.
162. Yuan, G.F.; Sun, B.; Yuan, J.; Wang, Q.M. Effects of different cooking methods on health-promoting compounds of broccoli. J. Zhejiang Univ. Sci. B 2009, 10, 580-588.